Finished product reference
Norepinephrine
Injection, Solution, Concentrate · Parenteral · 1 mg/1mL · 1 mL
- List code
- 52084
- Salt form
- Bitartrate
What it is and how it works
Mechanism of Action Norepinephrine is a peripheral vasoconstrictor (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Norepinephrine bitartrate injection is indicated to raise blood pressure in adult patients with severe, acute hypotension. Norepinephrine bitartrate injection is a catecholamine indicated for restoration of blood pressure in adult patients with acute hypotensive states.
Dosage and administration (summary)
Initial dose of 0.25 mL to 0.375 mL (from 8 mcg to 12 mcg of base) per minute, adjust the rate of flow to establish and maintain a low to normal blood pressure (usually 80 mm Hg to 100 mm Hg systolic) sufficient to maintain the circulation of vital organs. The average maintenance dose ranges from 0.0625 mL to 0.125 mL per minute (from 2 mcg to 4 mcg of base). Important Dosage and Administration Instructions Correct Hypovolemia Address hypovolemia before initiation of norepinephrine bitartrate injection therapy. If the patient does not respond to therapy, suspect occult hypovolemia . Administration Dilute norepinephrine bitartrate injection prior to use .
Contraindications
None. None.
Warnings and precautions
Tissue Ischemia : Avoid extravasation of norepinephrine bitartrate injection into the tissues, as local necrosis might ensue due to the vasoconstrictive action of the drug. Infuse norepinephrine bitartrate injection into a large vein. To prevent sloughing and necrosis in areas in which extravasation has taken place, the area should be infiltrated as soon as possible with 10 mL to 15 mL of saline solution containing from 5 mg to 10 mg of an adrenergic blocking agent. Hypotension After Abrupt Discontinuation : Sudden cessation of the infusion rate may result in marked hypotension.
Pregnancy
Pregnancy Risk Summary Limited published data consisting of a small number of case reports and multiple small trials involving the use of norepinephrine in pregnant women at the time of delivery have not identified an increased risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.
Storage and supply
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). . Store in original carton until time of administration to protect from light. Discard unused portion.
Source: Norepinephrine Bitartrate (Norepinephrine Bitartrate) — US FDA prescribing information, 2025-06-17, DailyMed. Summarised and shortened; the full label governs. Iranian registration, indications and labelling may differ.
Other presentations of the same active ingredient
- Injection, Solution, Concentrate · Parenteral · 0.5 mg/1mL · 10 mL53213
- Injection, Solution, Concentrate · Parenteral · 0.5 mg/1mL · 4 mL53212
- Injection, Solution, Concentrate · Parenteral · 1 mg/1mL · 10 mL1620
- Injection, Solution, Concentrate · Parenteral · 1 mg/1mL · 20 mL52091
- Injection, Solution, Concentrate · Parenteral · 1 mg/1mL · 4 mL50047
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.